Assessment of genetic predisposition to estrogen-dependent cancer/HTGR/(BRCA1- 3 mutations) + (CHEK2-1 mutation)

Diagnosis of estrogen-dependent cancer risk avoids complications associated with the use of hormone replacement therapy or contraception.

DNA test - BRCA1, CHEK2

Diagnosis of estrogen-dependent cancer risk (HTGR) includes testing for: 3 mutations in the BRCA1 gene, and 1 mutation in the CHEK2 gene.

The adverse effect of mutations in the BRCA1 and CHEK2 gene is particularly affected by women's hormone use before the age of 35 (hormonal contraception), increasing
10-fold the risk of developing cancer to about 90%. 

Gen BRCA1 .- BRCA1 mutations cause about 3% of all breast cancers and about 14% of all ovarian cancers. The presence of the mutation is associated with a 10-fold increased risk of breast cancer and a 30-40-fold increased risk of ovarian cancer

The CHEK2 gene - mutations in this gene are found in 16% of familial and 8% of all prostate cancers, 10% of kidney cancers, 10% of colorectal cancers, and are responsible for a 2-fold increased risk of papillary thyroid cancer.

The HTGR DNA test should be performed on every person to diagnose an increased risk of cancer.

In particular, the test should be performed in female patients:

• planning or taking hormone replacement therapy,
• Under 35 years of age planning and using hormonal contraception,

Order a home study and have it done at your convenience